Skip to main content
. 2021 Jul 5;12(1):3263–3274. doi: 10.1080/21655979.2021.1946632

Figure 4.

Figure 4.

Evaluating the efficacy of the five-lncRNA risk signature in the validation cohort. (a) LncRNA expression profiles, risk score distributions and patient survival in the validation cohort. (b) Survival curves for high-risk and low-risk groups decided by the risk signature in the validation cohort. (c-e) ROC of the five-lncRNA risk signature in predicting the 1-, 3-, and 5-year survival in the validation cohort